About Caprion

Caprion Proteomics Inc. Caprion's leading and proprietary proteomics discovery technologies - CellCarta® - enables the discovery of novel targets for therapeutics development and the identification of novel protein biomarkers that can significantly reduce risk and enhance clinical development productivity and decision making in pharmaceutical research. Caprion has established a number of biomarker collaborations projects with several companies including Wyeth, AstraZeneca, Merck, Pfizer, Boehringer Ingelheim, ICOS, Berlex and Vertex. Caprion also has three active strategic collaborations in the area of novel oncology target discovery and antibody development with Biogen-Idec, Abbott and J&J-Centocor.

Caprion is studying molecular events that enable bacteria to subvert the immune system. This work aims to define novel pathways and proteins that will provide a basis for the development of new immunotherapy targets, vaccines, and diagnostic candidates. Caprion will employ its distinctive quantitative protein profiling technologies to analyze pathogen and host proteins involved during Brucella infection. Brucella is a potential bioterrorism agent and is responsible for considerable global economic losses due to disease in cattle. However, the study layout and methodologies used are not specific to Brucella, but represent an approach applicable to many intracellular bacteria such as Salmonella, mycobacteria, Bacillus anthracis and others.

Goals & Objectives | Presentation | Publications | Key Players

[ click on a link above for further information or here to see page in full ]

Goals and Objectives

Study compositional changes to cellular phagosomes
Study bacterial virulence factors
Study changes in the plasma membrane
Study MHC peptide presentation

Presentation

The presentation below includes more information regarding target discovery approach as well as program, data and Website deliverables and milestones.

Program Overview: Caprion Pharmaceuticals [3/22/05, PPT, 17 slides/258KB]

Publications

An evaluation of multidimensional fingerprinting in the context of clinical proteomics (Membership to or purchase fromWiley Interscience required to view full article) | Abstract
Lekpor K, Benoit M-J, Butler H, Schirm M, Vasilescu D, Bonter K, Chelsky D, Hugo P, Hunter J, Opitek G, Paramithiotis E, Kearney P.
Proteomics. 2007 Apr 19;1(5):457-66
Extensive cell envelope modulation is associated with virulence in Brucella abortus (Membership or subscription to ACS Publications required to view full article) | Abstract | Supplemental
Lamontagne J, Butler H, Chaves-Olarte E, Hunter J, Schirm M, Paquet C, Tian M, Kearney P, Hamaidi L, Chelsky D, Moriyón I, Moreno E, Paramithiotis E.
J Proteome Res. 2007 Apr 8;6(4):1519-29 - PMID: 17343405

Key Players

Daniel Chelsky, Ph.D.
Chief Scientific Officer

Lyes Hamaidi (IWG member)
Director, IT

Paul Kearney, Ph.D. (IWG member)
Executive Director, Bioinformatics

Joanna Hunter, Ph.D.
Director of Protein Analysis

Eustache Paramithiotis, Ph.D. (Principal Investigator)
Director, Cell and Molecular Biology